Lyra therapeutics reports third quarter 2023 financial results and provides corporate update

– additional phase 2 beacon trial ct scan data demonstrated statistically significant improvement in sinus opacification with lyr-220 and provided radiological evidence of improvement in chronic rhinosinusitis (crs) patients who have had prior ethmoid sinus surgery –
LYRA Ratings Summary
LYRA Quant Ranking